Suppr超能文献

正在临床开发中的白喉、破伤风和百日咳疫苗的综述。

Review of diphtheria, tetanus and pertussis vaccines in clinical development.

机构信息

Pfizer Ltd, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK.

出版信息

Expert Rev Vaccines. 2011 May;10(5):605-15. doi: 10.1586/erv.11.60.

Abstract

Diphtheria, tetanus and pertussis vaccines have formed the cornerstone of childhood immunization programs for decades. Historically, these have comprised diphtheria and tetanus toxoids combined with inactivated whole-cell pertussis. More recently, advances have been made with the development of purified acellular pertussis vaccines, with improved reactogenicity profiles, and formulation with additional vaccines such as Haemophilus influenzae type b, hepatitis B virus and inactivated poliovirus. Development is currently focused on maximizing the number of vaccines that can be combined in a single formulation and strategies to provide protection against pertussis before the commencement of routine infant immunization.

摘要

白喉、破伤风和百日咳疫苗已成为儿童免疫计划的基石数十年。历史上,这些疫苗包括白喉和破伤风类毒素,以及灭活全细胞百日咳。最近,随着精制无细胞百日咳疫苗的发展,其在改善反应原性方面取得了进展,并与其他疫苗(如乙型流感嗜血杆菌、乙型肝炎病毒和灭活脊髓灰质炎病毒)联合使用。目前的研究重点是最大限度地增加可在单一配方中组合的疫苗数量,并制定在常规婴儿免疫接种开始之前提供针对百日咳保护的策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验